JP5568609B2 - ヘルペスウイルス感染の治療のためのペプチド - Google Patents
ヘルペスウイルス感染の治療のためのペプチド Download PDFInfo
- Publication number
- JP5568609B2 JP5568609B2 JP2012186755A JP2012186755A JP5568609B2 JP 5568609 B2 JP5568609 B2 JP 5568609B2 JP 2012186755 A JP2012186755 A JP 2012186755A JP 2012186755 A JP2012186755 A JP 2012186755A JP 5568609 B2 JP5568609 B2 JP 5568609B2
- Authority
- JP
- Japan
- Prior art keywords
- hervip
- hsv
- infection
- pharmaceutical composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 title description 6
- 208000029433 Herpesviridae infectious disease Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 230000000840 anti-viral effect Effects 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000003612 virological effect Effects 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 5
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 208000034309 Bacterial disease carrier Diseases 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 210000002826 placenta Anatomy 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010019973 Herpes virus infection Diseases 0.000 description 5
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 108010008118 glutamyl-leucyl-valyl-isoleucyl-serine Proteins 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- -1 infusions Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
細胞アッセイを用いて、単純ヘルペスウイルスの感染率を決定する。HSV−2の阻害剤は、このアッセイにおいて感染率を低下させる。
Claims (3)
- アミノ酸配列
NH2−VCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH−COOH(配列番号1)に対して少なくとも95%の同一性を有し、単純ヘルペスウイルスに対する阻害活性を有するペプチドを含む、単純ヘルペスウイルスを伴う感染により引き起こされるウイルス性疾患治療用医薬組成物であって、
但し、配列番号1または3と同一のアミノ酸配列を除く、医薬組成物。 - 前記ウイルス性疾患が細菌の不定着化を引き起こさない、請求項1に記載の医薬組成物。
- 注入、軟膏、錠剤、スプレー、「持続放出」カプセル及び類似調製物のために調合された製剤中での、及び/又は他の抗ウイルス治療剤との組み合わせによる、請求項1又は2に記載の医薬組成物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60231304P | 2004-08-18 | 2004-08-18 | |
EP04019552 | 2004-08-18 | ||
US60/602,313 | 2004-08-18 | ||
EP04019552.1 | 2004-08-18 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007526458A Division JP5101280B2 (ja) | 2004-08-18 | 2005-08-16 | ヘルペスウイルス感染の治療のためのペプチド |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013028612A JP2013028612A (ja) | 2013-02-07 |
JP5568609B2 true JP5568609B2 (ja) | 2014-08-06 |
Family
ID=35782047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012186755A Expired - Fee Related JP5568609B2 (ja) | 2004-08-18 | 2012-08-27 | ヘルペスウイルス感染の治療のためのペプチド |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP5568609B2 (ja) |
DE (1) | DE602005010590D1 (ja) |
HK (1) | HK1106144A1 (ja) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE411812T1 (de) * | 2004-08-18 | 2008-11-15 | Ipf Pharmaceuticals Gmbh | Peptide zur behandlung von infektionen mit dem herpes-virus |
-
2005
- 2005-08-16 DE DE602005010590T patent/DE602005010590D1/de active Active
-
2007
- 2007-10-25 HK HK07111530.7A patent/HK1106144A1/xx not_active IP Right Cessation
-
2012
- 2012-08-27 JP JP2012186755A patent/JP5568609B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2013028612A (ja) | 2013-02-07 |
DE602005010590D1 (de) | 2008-12-04 |
HK1106144A1 (en) | 2008-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2875826B1 (en) | Composition for preventing or treating sepsis | |
US9872885B2 (en) | Antimicrobial and anti-inflammatory peptides | |
AU2022203288A1 (en) | Antimicrobial therapy | |
EP0378364A2 (en) | Analogues of PF4 and fragments thereof, and pharmaceutical compositions containing them | |
CA2456477A1 (en) | Antimicrobial cationic peptides and formulations thereof | |
JP5101280B2 (ja) | ヘルペスウイルス感染の治療のためのペプチド | |
TWI511737B (zh) | 可用於治療多種皮膚病之衍生自人類c-x-c趨化因子之四胜肽 | |
KR101341210B1 (ko) | 신규한 항균 펩타이드 및 이의 용도 | |
EP3193906B1 (en) | Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation | |
EP2125878B1 (en) | Short bio-active peptides for cellular and immunological modulation | |
EP3583934B1 (en) | Biocidal agent | |
JP5568609B2 (ja) | ヘルペスウイルス感染の治療のためのペプチド | |
WO1993024143A1 (en) | A method for using lipoprotein associated coagulation inhibitor to treat sepsis | |
CN112402592B (zh) | Spink7蛋白在制备促进过度炎症创面愈合的药物中的应用 | |
JP2017524000A (ja) | 腹膜炎の治療のための組成物 | |
US5698519A (en) | Polypeptide specifically inhibiting cathepsin L | |
EP3270950B1 (en) | Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases | |
WO2002029082A1 (en) | Endothelial cell mitogen bioassay | |
KR20220164450A (ko) | Agkistrodon piscivorus piscivorus 또는 Naja melanoleuca로부터 유래된 신규한 펩타이드, 및 이를 포함하는 베체트병 또는 류마티스 관절염의 치료용 조성물 | |
CN117229358A (zh) | 一种短肽抑制剂及其在制备治疗牙周病药物中的应用 | |
Bersani et al. | Rapid killing of actinomycin D-treated tumor cells-cytotoxicity of cell-free monocyte supernatants | |
KR20120071736A (ko) | 애기뿔소똥구리에서 분리한 펩타이드를 유효성분으로 포함하는 창상 치료용 또는 항균용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20131203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140225 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140312 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140418 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140529 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140617 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140623 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5568609 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |